文献速递系统性红斑狼疮

系统性红斑狼疮妊娠患者羟氯喹水平与母胎结局

Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

前瞻性GR2研究纳入174例接受羟氯喹的妊娠系统性红斑狼疮患者,评估妊娠早期全血羟氯喹水平与母胎结局的关系。妊娠早期亚治疗水平(≤500 ng/ml)和严重不依从水平(≤200 ng/ml)与严重母体 flare 相关,但与不良妊娠结局无关。

要点

  • 妊娠早期羟氯喹≤500 ng/ml者严重 flare 发生率8.8%,>500 ng/ml者0.7%(P=0.02)。
  • 妊娠早期羟氯喹≤200 ng/ml者严重 flare 发生率13.3%,>200 ng/ml者1.3%(P=0.04)。
  • 不良妊娠结局在羟氯喹≤500 ng/ml与>500 ng/ml间无显著差异(23.5% vs 14.3%,P=0.19)。

核心结论

  • 妊娠早期亚治疗水平(≤500 ng/ml)和严重不依从水平(≤200 ng/ml)的羟氯喹与严重母体 flare 相关,但与不良妊娠结局无关。

研究设计与样本

  • 前瞻性GR2研究纳入174例接受羟氯喹且至少有一次妊娠早期全血羟氯喹检测的妊娠系统性红斑狼疮患者,中位年龄32.1岁(IQR 28.8-35.2)。

主要发现

  • 30例(17.2%)患者发生 flare,其中4例(2.3%)为严重 flare;28例(16.1%)发生不良妊娠结局。
  • 不良妊娠结局在羟氯喹≤500 ng/ml组与>500 ng/ml组无显著差异(23.5% vs 14.3%,P=0.19)。
  • 不良妊娠结局在羟氯喹≤200 ng/ml组与>200 ng/ml组无显著差异(20.0% vs 15.7%,P=0.71)。
  • 总体母体 flare 率在各羟氯喹切点间无显著差异,但严重 flare 在≤500 ng/ml组高于>500 ng/ml组(8.8% vs 0.7%,P=0.02),在≤200 ng/ml组高于>200 ng/ml组(13.3% vs 1.3%,P=0.04)。

关键数值与推荐

  • 妊娠早期全血羟氯喹≤200 ng/ml定义为严重不依从。
  • 主要结局为妊娠中晚期母体 flare 和不良妊娠结局(胎儿/新生儿死亡、胎盘功能不全伴早产、小于胎龄儿)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Data about hydroxychloroquine (HCQ) levels during pregnancy are sparse. We assessed HCQ whole-blood levels at first trimester of pregnancy as a potential predictor of maternal and obstetric/fetal outcomes in patients with systemic lupus erythematosus (SLE). METHODS: We included pregnant SLE patients enrolled in the prospective GR2 study receiving HCQ, with at least one available first-trimester whole-blood HCQ assay. We evaluated several cut-offs for HCQ whole-blood levels, including ≤200 ng/ml for severe non-adherence. Primary outcomes were maternal flares during the second and third trimesters of pregnancy, and adverse pregnancy outcomes (APOs: fetal/neonatal death, placental insufficiency with preterm delivery, and small-for-gestational-age neonates). RESULTS: We included 174 patients (median age: 32.1 years, IQR 28.8-35.2). Thirty (17.2%) patients had flares, four (2.3%) being severe. APOs occurred in 28 patients (16.1%). There were no significant differences in APOs by HCQ level for either those with subtherapeutic HCQ levels (≤500 ng/ml vs >500 ng/ml: 23.5% vs 14.3%, P = 0.19) or those with non-adherent HCQ levels (≤200 ng/ml vs >200 ng/ml: 20.0% vs 15.7%, P = 0.71). Similarly, the overall rate of maternal flares did not differ significantly by HCQ level cut-off, but patients with subtherapeutic (HCQ ≤500 ng/ml: 8.8% vs 0.7%, P = 0.02) and non-adherent HCQ levels (≤200 ng/ml: 13.3% vs 1.3%, P = 0.04) had significantly more severe flares. CONCLUSION: In this large prospective study of pregnant SLE patients, first-trimester subtherapeutic (≤500 ng/ml) and severe non-adherent (≤200 ng/ml) HCQ levels were associated with severe maternal flares, but not with APOs. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02450396.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Alle G, Guettrot-Imbert G, Larosa M, et al. Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients. Rheumatology (Oxford). 2025. PMID: 38837707. doi:10.1093/rheumatology/keae302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。